Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 3:14:1331055.
doi: 10.3389/fonc.2024.1331055. eCollection 2024.

Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses

Suyu Gu #  1   2 , Yuting Liu #  3 , Yufan Huang #  1 , Wenzheng Lin  1   2 , Ke Li  1   2
Affiliations

Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses

Suyu Gu et al. Front Oncol. .

Abstract

Background: In recent years, novel therapies targeting specific molecular pathways and immunotherapies have exhibited promising outcomes for treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Our work aimed to assess the effectiveness and safety of these emerging treatment regimens for this disease.

Material and methods: We systematically searched databases including PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials their inception to August 2023 to identify relevant randomized controlled trials (RCTs). The quality of eligible RCTs was evaluated with the Cochrane risk-of-bias tool, version 2 (RoB2). Investigated outcomes encompassed progression-free survival (PFS), overall survival (OS), disease-free survival (DFS), pathologic complete remission (pCR), and adverse events (AEs). They were expressed as hazard ratio (HR) with 95% conference intervals (CI) or risk ratio (RR) with 95% CI.

Results: Our analysis identified a total of 28 RCTs suitable for inclusion in the NMA. Regarding the PFS, all these treatment regimens exhibited comparable effectiveness. In terms of OS, Capecitabine+Trastuzumab, Lapatinib+Trastuzumab and Pyrotinib+Capecitabine exhibited better effect compared to other treatments. Regarding pCR and AEs, all these treatment regimens exhibited comparable effectiveness, especially Lapatinib+Trastuzumab and Pyrotinib+Capecitabine.

Conclusion: Our study highlights the prominent role of targeted therapies and immunotherapies in treating HER2-positive breast cancer. The efficacy of trastuzumab-containing regimens was superior to other treatment options, while maintaining a comparable safety profile. Based on these findings, trastuzumab-containing regimens emerge as a preferable and recommended choice in clinical practice for managing HER2-positive breast cancer.

Systematic review registration: PROSPERO, identifier CRD42023414348.

Keywords: HER2-positive; breast cancer; efficacy; immunotherapies; meta-analysis; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Eligibility of studies for inclusion in meta-analysis.
Figure 2
Figure 2
Risk of bias summary.
Figure 3
Figure 3
Plots of overall survival (OS). (A) Network plot. (B) Forest plot. (C) Ranking plot.
Figure 4
Figure 4
Plots of pathologic complete response (pCR). (A) Network plot. (B) Ranking plot. (C) Forest plot.
Figure 5
Figure 5
Plots of Adverse events (AEs). (A) Forest plot. (B) Ranking plot. (C) Network plot.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. (2017) 50:33. doi: 10.1186/s40659-017-0140-9 - DOI - PMC - PubMed
    1. Cordo Russo RI, Chervo MF, Madera S, Charreau EH, Elizalde PV. Nuclear erbB-2: A novel therapeutic target in erbB-2-positive breast cancer? Hormones Cancer. (2019) 10:64–70. doi: 10.1007/s12672-018-0356-3 - DOI - PMC - PubMed
    1. Asif HM, Sultana S, Ahmed S, Akhtar N, Tariq M. HER-2 positive breast cancer - a mini-review. Asian Pacific J Cancer Prev APJCP. (2016) 17:1609–15. doi: 10.7314/APJCP.2016.17.4.1609 - DOI - PubMed
    1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. (1989) 244:707–12. doi: 10.1126/science.2470152 - DOI - PubMed
    1. Nader-Marta G, Martins-Branco D, de Azambuja E. How we treat patients with metastatic HER2-positive breast cancer. ESMO Open. (2022) 7:100343. doi: 10.1016/j.esmoop.2021.100343 - DOI - PMC - PubMed

Publication types